Science & Research
GeoVax to Showcase Innovative Vaccines and Therapies at BIO International Convention 2025
GeoVax Labs, Inc. announces its participation in the 2025 BIO International Convention, highlighting its pipeline of vaccines and immunotherapies for infectious diseases and cancer, underscoring the company's role in advancing global health solutions.
Study Identifies 528 Frequency as Key to Healing and Life Extension
A groundbreaking study reveals the 528Hz frequency and 528nm green light as universal constants with potential to revolutionize healing, stem cell activation, and life extension, bridging ancient wisdom with modern science.
New Study Highlights Challenges and Systemic Barriers for Liver Cancer Patients
A recent study reveals the significant hurdles faced by hepatocellular carcinoma patients, including delayed diagnoses and social stigma, calling for systemic healthcare reforms.
Chinese Scientists Propose Innovative Energy Solution for Mars
Researchers from the University of Science and Technology of China suggest using the Martian atmosphere for energy generation and storage, offering a potential solution for future Mars settlers and long-term research missions.
Telomir Pharmaceuticals Reports Significant Preclinical Breakthrough with Telomir-1 in Wilson’s Disease Model
Telomir Pharmaceuticals' preclinical data reveals Telomir-1's potential to reverse symptoms of Wilson’s disease, a rare copper accumulation disorder, marking a significant step towards human trials and offering hope for patients.
GeoVax Advances Mpox Vaccine Development Amid WHO's Global Health Emergency Declaration
GeoVax Labs, Inc. is responding to the WHO's declaration of Mpox as a global public health emergency by advancing its GEO-MVA vaccine, aiming to address the urgent need for diversified vaccine supply and enhanced pandemic preparedness.
Lifordi Immunotherapeutics Unveils Promising Preclinical Data for LFD-200 at EULAR 2025
Lifordi Immunotherapeutics has presented preclinical data on LFD-200, a novel antibody-drug conjugate targeting autoimmune and inflammatory diseases, showing efficacy without systemic toxicity, marking a potential breakthrough in treatment options.
American Heart Association Launches Data Challenge to Uncover Inflammation's Role in Heart Disease
The American Heart Association has initiated the Systemic Inflammation Data Challenge to explore the connection between inflammation, marked by elevated hsCRP levels, and cardiovascular disease, aiming to improve health outcomes through advanced data science.
Creative Biolabs Advances Microbiome-Based Drug Development with Enhanced LBP Analytics
Creative Biolabs has introduced an advanced microbial service platform to streamline the development of microbiome-based drugs, addressing key challenges in strain characterization, contaminant detection, and formulation stability.
Pacylex Pharmaceuticals Showcases Promising NMT Inhibitors at BIO Annual Meeting
Pacylex Pharmaceuticals Inc. highlights its innovative N-myristoyltransferase inhibitors (NMTis) at the BIO International Convention, showcasing potential breakthroughs in cancer treatment through oral zelenirstat and ADC payloads.
GeoVax to Showcase Positive Immune Response Data for GEO-CM04S1 in CLL Patients at EHA 2025 Congress
GeoVax Labs, Inc. will present clinical data at the European Hematology Association 2025 Congress, demonstrating the superior cellular immune response of its GEO-CM04S1 vaccine in chronic lymphocytic leukemia patients compared to mRNA-based vaccines.
Tonix Pharmaceuticals to Showcase Innovations at 2025 BIO International Convention
Tonix Pharmaceuticals Holding Corp. is set to present at the 2025 BIO International Convention, highlighting its advancements in pain management and public health solutions, including a potential new treatment for fibromyalgia.
Oragenics Inc. to Showcase Concussion Treatment Candidate at Major 2025 Biotech and Neurotrauma Events
Oragenics Inc. (NYSE American: OGEN) is set to present its intranasal neurosteroid candidate for concussion treatment, ONP-002, at two significant 2025 events, highlighting its potential impact on neurology and pharmaceutical sectors.
Tevard Biosciences Appoints Dr. Elisabeth Gardiner as Chief Scientific Officer to Advance tRNA-Based Therapies
Tevard Biosciences has appointed Dr. Elisabeth Gardiner as its new Chief Scientific Officer, marking a significant step in advancing its tRNA-based therapies for genetic diseases, with implications for treating conditions like Duchenne Muscular Dystrophy and TTN-related dilated cardiomyopathy.
Legal Notice Calls for Investigation into COVID-19 Origins and Vaccine Technologies
Dr. Leonard G. Horowitz has issued a legal notice urging a thorough investigation into the origins of COVID-19 and the technologies used in vaccine development, highlighting concerns over potential health risks and the need for transparency.
Alfa Cytology Launches PARP Inhibitors Development Services for Advanced Cancer Treatment
Alfa Cytology has introduced comprehensive development services for PARP inhibitors, offering a promising avenue for more precise and personalized cancer treatments, particularly for cancers with genetic mutations like BRCA1 and BRCA2.
American Heart Association Certifies First Comprehensive Chest Pain Centers in India and Mexico
The American Heart Association has certified the first Comprehensive Chest Pain Centers in India and Mexico, marking a significant advancement in global cardiac care and addressing the leading cause of death worldwide.
GeoVax's Multi-Antigen COVID-19 Vaccine Shows Promise Against Variants
GeoVax Labs, Inc. reports preclinical success of its multi-antigen COVID-19 vaccines, GEO-CM04S1 and GEO-CM02, in providing durable, cross-reactive immunity against SARS-CoV-2 variants, including Omicron XBB.1.5, highlighting the potential for broader protection without the need for frequent updates.
LEKSUM and SLU Partner to Pioneer Muscle Research in Unique ICU Lab
LEKSUM LLC's collaboration with SLU establishes a groundbreaking muscle research lab, led by Dr. Lars Larsson, to study long-term ICU conditions and develop therapies for muscle myopathies affecting millions annually.
Urgent Call for Parliamentary Intervention to Redirect CERN Funding Towards Life-Saving Innovations
The Crosetto Foundation highlights decades of misallocated funding at CERN, advocating for the adoption of Dario Crosetto's 3D-Flow technology to save billions in taxpayer money and accelerate advancements in cancer detection and particle physics.
Soligenix's HyBryte(TM) Offers New Hope for CTCL Patients with FDA Orphan Drug Designation
Soligenix Inc. advances in the treatment of Cutaneous T-cell lymphoma (CTCL) with HyBryte(TM), a photodynamic therapy showing promise in clinical trials and receiving Orphan Drug Designation, addressing a critical need for effective therapies in this rare disease.
Kamada Intensifies Efforts to Highlight CYTOGAM's Role in CMV Management for Transplant Patients
Kamada Ltd. is amplifying its commitment to organ transplant patients by enhancing awareness and research around CYTOGAM, its treatment for cytomegalovirus (CMV), a potentially deadly complication for transplant recipients.
Reimagine Jesus Foundation Releases Provocative Spiritual Work
The Reimagine Jesus Foundation introduces 'Reimagine Jesus: Gospel for the 21st Century', a book by Mike Oslance that revisits Jesus' teachings through modern scientific and psychological perspectives, challenging traditional doctrines.
Yandex Open-Sources Neural Network to Accelerate Coastal Cleanup Efforts
A collaborative effort between Yandex B2B Tech, Yandex School of Data Analysis, and Far Eastern Federal University has resulted in an open-source neural network that significantly speeds up the cleanup of remote coastal areas, addressing the urgent global issue of marine plastic pollution.
Calidi Biotherapeutics Unveils Promising Data on CLD-401 at ASCO 2025
Calidi Biotherapeutics Inc. presents groundbreaking data on its lead candidate CLD-401 at the ASCO Annual Meeting, showcasing advancements in systemic oncolytic targeted immunotherapies with potential implications for cancer treatment.
CNS Pharmaceuticals Inc. to Showcase Glioblastoma Treatment Advancements at Brain Tumor Biotech Summit
CNS Pharmaceuticals Inc. will present promising data on its brain-penetrating taxane candidate, TPI 287, at the upcoming Brain Tumor Biotech Summit, highlighting potential breakthroughs in treating glioblastoma and other CNS tumors.
Telomir Pharmaceuticals Reports Preclinical Breakthrough in Age-Reversal with Telomir-1
Telomir Pharmaceuticals' preclinical results for Telomir-1 show promising age-reversal effects in a zebrafish model of Werner Syndrome, highlighting potential advancements in longevity science.
Annovis Bio Inc. to Host Webcast on Alzheimer’s and Parkinson’s Programs Updates
Annovis Bio Inc. (NYSE: ANVS) is set to host a webcast featuring CEO Maria Maccecchini, Ph.D., to discuss updates on its Phase 3 trial for early Alzheimer’s disease and FDA feedback on its Parkinson’s disease program, highlighting the company's progress in neurodegenerative disease treatments.
Vaughn J. Crichlow Appointed Dean of School of Justice Studies at Roger Williams University
Dr. Vaughn J. Crichlow, a seasoned educator and researcher with over two decades of experience in criminal justice, has been named the new dean of the School of Justice Studies at Roger Williams University, signaling a strong commitment to advancing justice education and research.
New Therapeutic Target Offers Hope in Preventing Cancer from Chronic Gut Inflammation
Research highlights a promising therapeutic target that could prevent cancer in patients suffering from chronic inflammatory bowel diseases like Crohn’s disease and ulcerative colitis, offering new hope for young patients particularly affected by these conditions.